INDEMNIFICATION AGREEMENTIndemnification Agreement • July 7th, 2021 • Icosavax, Inc. • Biological products, (no disgnostic substances) • Delaware
This Indemnification Agreement (“Agreement”) is made as of ________ __, 20__ by and between Icosavax, Inc., a Delaware corporation (the “Company”), and ______________, [a member of the Board of Directors/ an officer] of the Company (“Indemnitee”). This Agreement supersedes and replaces any and all previous Agreements between the Company and Indemnitee covering indemnification and advancement.
GLOBAL ACCESS AND PRICE COMMITMENT AGREEMENT Investment ID [***]Global Access and Price Commitment Agreement • July 7th, 2021 • Icosavax, Inc. • Biological products, (no disgnostic substances)
This Global Access and Price Commitment Agreement (“Agreement”), effective as of the date of the last signature below, is made by and between the Bill & Melinda Gates Foundation (the “Foundation”) and Icosavax, Inc. (“Icosavax”), in connection with the Grant Agreement for [***] between the Parties effective September 24, 2020 (“Grant Agreement”). Unless otherwise defined in this Agreement, capitalized terms have the same meaning as given in the Grant Agreement. This Agreement is a part of, and is incorporated into, the Grant Agreement.
Patent License Agreement Agreement No. [***]Patent License Agreement • July 7th, 2021 • Icosavax, Inc. • Biological products, (no disgnostic substances) • Texas
This Patent License Agreement is between the Licensor and the Licensee identified below (collectively, “Parties”, or singly, “Party”).
LICENSE AND EXCLUSIVE OPTION AGREEMENT BETWEEN ICOSAVAX, INC. AND UNIVERSITY OF WASHINGTON FOR COMPUTATIONALLY DESIGNED NANOPARTICLES AND VACCINES BASED UPON SUCH DESIGNS UW COMOTION AGREEMENT REF. [***]License and Exclusive Option Agreement • July 7th, 2021 • Icosavax, Inc. • Biological products, (no disgnostic substances) • Washington
This License and Exclusive Option Agreement (this “Agreement”), effective as of the date of last signature (the “Effective Date”), is made and entered into between the University of Washington, a public institution of higher education and an agency of the state of Washington, (“University”), and Icosavax, Inc., a for profit corporation under the laws of Delaware (“Company”).
EXCLUSIVE LICENSE AGREEMENT BETWEEN ICOSAVAX, INC. AND UNIVERSITY OF WASHINGTON FOR COMPUTATIONALLY DESIGNED NANOPARTICLES AND VACCINES BASED UPON SUCH DESIGNS UW COMOTION AGREEMENT REF. [***]Exclusive License Agreement • July 7th, 2021 • Icosavax, Inc. • Biological products, (no disgnostic substances) • Washington
This Exclusive License Agreement (this “Agreement”), effective as of the date of last signature (the “Effective Date”), is made and entered into between the University of Washington, a public institution of higher education and an agency of the state of Washington, (“University”), and Icosavax, Inc., a for profit corporation under the laws of Delaware (“Company”).
ICOSAVAX, INC.Employment Agreement • July 7th, 2021 • Icosavax, Inc. • Biological products, (no disgnostic substances) • California
Icosavax, Inc. (the “Company”) is pleased to offer you (the “Employee”) a position on the terms set forth in this letter (this “Agreement”). In consideration of the mutual promises herein contained, the parties agree as follows:
PUBLIC HEALTH SERVICE PATENT LICENSE AGREEMENT NONEXCLUSIVE – SUBLICENSABLE and BIOLOGICAL MATERIALS LICENSE-NON-EXCLUSIVE This Agreement is based on the model Patent License Non-Exclusive Sublicensable Agreement adopted by the U.S. Public Health...Patent License Agreement • July 7th, 2021 • Icosavax, Inc. • Biological products, (no disgnostic substances) • District of Columbia
This Patent License Agreement, hereinafter referred to as the “Agreement”, consists of this Cover Page, an attached Agreement, a Signature Page, Appendix A (List of Patent(s) or Patent Application(s)), Appendix B (Fields of Use and Territory), Appendix C (Royalties), Appendix D (Benchmarks and Performance), Appendix E (Commercial Development Plan), Appendix F (Example Royalty Report), Appendix G (Royalty Payment Options, and Appendix H (Shipping Information).
